Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,553.27 37.00 0.25%
TOPIX 1,173.74 0.37 0.03%
HANG SENG 22,760.24 64.23 0.28%

Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen



  Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on
               Alexion, BioMarin, Onyx, Questcor, and ImmunoGen

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, June 14, 2013

NEW YORK, June 14, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Alexion
Pharmaceuticals, Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ:
BMRN), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Questcor Pharmaceuticals,
Inc. (NASDAQ: QCOR), and ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Alexion Pharmaceuticals, Inc. Research Report

On June 5, 2013, Alexion Pharmaceuticals, Inc. (Alexion) announced that the
results of trials published in The New England Journal of Medicine (NEJM)
showed that chronic Soliris (eculizumab) therapy is effective in the treatment
of patients with atypical hemolytic uremic syndrome (aHUS), a genetic,
life-long, ultra-rare disease associated with vital organ failure and
premature death. According to results of two pivotal studies published in the
NEJM, chronic Soliris treatment substantially inhibits systemic
complement-mediated thrombotic microangiopathy (TMA), decreases the need for
TMA-related intervention, and results in significant and sustained improvement
in platelet count. It also increasingly improves renal function across patient
groups over time, and is associated with substantial kidney recovery in
patients with aHUS. Soliris was approved for the treatment of patients with
aHUS in the US, Europe, and other countries based on data from the two
prospective studies published in NEJM. The Full Research Report on Alexion
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/451f_ALXN]

--

BioMarin Pharmaceutical Inc. Research Report

On June 5, 2013, BioMarin Pharmaceutical Inc. (BioMarin) announced that it has
initiated the Phase 3 program for PEG-PAL (PEGylated recombinant Phenylalanine
Ammonia Lyase) for the treatment of phenylketonuria (PKU). "Adult patients
with PKU and patients on the severe end of the disease spectrum still
represent a very high unmet medical need. With PEG-PAL, it may be possible to
provide a treatment benefit to this population," said Hank Fuchs, M.D., Chief
Medical Officer of BioMarin. The Phase 3 study (165-301) is an open-label,
multi-center study to assess the safety and tolerability of an induction,
titration, and maintenance dose regimen of PEG-PAL self-administered by
approximately 90 naïve adult PKU subjects. After completion of the open label
165-301 study, subjects are expected to enroll in 165-302, a Phase 3
double-blind, placebo-controlled, randomized discontinuation study to evaluate
the efficacy and safety of PEG-PAL self-administered by adults with PKU. The
Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/936c_BMRN]

--

Onyx Pharmaceuticals, Inc. Research Report

On June 3, 2013, Onyx Pharmaceuticals, Inc. (Onyx) and the University of
California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer
Center announced the formation of the Oncology Innovation Alliance (OIA). OIA
is a public-private partnership focusing on the discovery and development of
novel therapies and their potential role in treating various types of
hematologic cancers and solid tumors. The alliance intends to transform cancer
care by harnessing the expertise in fundamental science and medicine at both
UCSF and Onyx to address the full continuum of that care, from prediction and
diagnosis to new therapies and post-treatment monitoring, to identify
opportunities to improve the patient experience and outcomes. The term of the
agreement extends for three years. The Full Research Report on Onyx
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/fcf8_ONXX]

--

Questcor Pharmaceuticals, Inc. Research Report

On June 10, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced the
addition of Angus C. Russell, recently-retired CEO of Shire plc, to Questcor's
Board of Directors. "Angus is a respected biopharmaceutical industry leader
with a proven track in specialty pharmaceuticals," said Virgil D. Thompson,
Chairman of Questcor's Board of Directors. "We look forward to benefitting
from Angus' 32 years of experience in the specialty pharmaceutical industry as
we continue to focus on the treatment of patients with serious,
difficult-to-treat autoimmune and inflammatory disorders." "The growth of
scientific knowledge regarding the importance of melanocortin receptors in
immunomodulation provides Questcor with a large potential growth opportunity
over the next few years," Angus added. Further, on May 29, 2013, the Company's
Board of Directors declared a quarterly cash dividend of $0.25 per share to
shareholders of record at the close of business on July 22, 2013, payable on
or about July 30, 2013. The Full Research Report on Questcor Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/ad11_QCOR]

--

ImmunoGen, Inc. Research Report

On June 3, 2013, ImmunoGen, Inc. (ImmunoGen) announced the presentation of the
first clinical data with the Company's IMGN853 product candidate. The data
belong to the ongoing dose-finding portion of a Phase I clinical assessment of
the compound, which is a potential treatment for many ovarian, endometrial,
and non-small cell lung cancers, as well as other FRα-overexpressing cancers.
The dose-finding portion of the Phase I clinical trial is designed to
establish the maximum tolerated dose of IMGN853 and to define its
dose-limiting toxicity (DLT). At the time of data cutoff for presentation, 18
patients had received IMGN853 at doses ranging from 0.15 to 7 mg/kg. DLT, seen
at 7 mg/kg, was reversible blurred vision with epithelial corneal changes.
While the assessment is designed to evaluate the safety of IMGN853 and
establish its maximum tolerated dose, evidence of clinical activity is also
being identified. The Company expects to begin the disease-specific,
dose-expansion phase of the trial in late 2013. The Full Research Report on
ImmunoGen, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/18c3_IMGN]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquires, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement